Veradermics Completes Enrollment in its Phase 2/3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss, Advancing Development of the Potential First-Ever Extended-Release Oral Minoxidil

Gaurav Munj2025-12-11T12:17:41+00:00 Newsroom 2025 News Top News Archives In the News Media Inquiries Registration-directed program also includes a second Phase 3 trial in males and a Phase 2/3 trial in females with pattern hair loss, which are actively enrolling​ Full data from ongoing VDPHL01 Phase 2 trial in males and...

Veradermics Advances VDPHL01 in Phase 2/3 Clinical Trial for Female Pattern Hair Loss, Marking a Milestone in the Development of the Potential First-Ever Oral Prescription Treatment for Women

Gaurav Munj2025-12-11T10:54:47+00:00 Newsroom 2025 News Top News Archives In the News Media Inquiries VDPHL01 has the potential to be the first and only extended-release oral minoxidil for women and men with pattern hair loss, a condition affecting an estimated 30 million women and 50 million men in the United...

Veradermics Announces Oversubscribed $150 Million Series C Financing to Advance VDPHL01 Through Multiple Phase 3 Trials as Potentially the First Non-Hormonal Oral Therapeutic for Hair Regrowth in Women and Men

Gaurav Munj2025-12-11T10:55:05+00:00 Newsroom 2025 News Top News Archives In the News Media Inquiries VDPHL01 is in multiple Phase 3 clinical trials as the potential first and only extended-release oral minoxidil for women and men with pattern hair loss – one of the largest aesthetics conditions worldwide, with no new...

Veradermics Raises $75 Million in Series B Financing and Initiates Phase 2/3 Trial for Hair Loss

Gaurav Munj2025-12-11T10:55:30+00:00 Newsroom 2024 News Top News Archives In the News Media Inquiries Investment to fund pivotal trials of VDPHL01, an oral investigational medicine for androgenetic alopecia (AGA), known as pattern hair loss (PHL) in men and women Androgenetic alopecia/pattern hair loss is a large and unsatisfied market, affecting an...

Veradermics CEO Reid Waldman is selected as a Forbes 30 Under 30 for 2024

Gaurav Munj2025-12-11T10:56:02+00:00 Newsroom 2023 News Top News Archives In the News Media Inquiries NEW HAVEN, Conn., Nov. 29, 2023 /PRNewswire-PRWeb/ -- Veradermics Inc., a clinical-stage medical dermatology company developing new therapeutics for a range of skin and hair loss conditions, today announced that Co-Founder and CEO, Reid Waldman, has...

Veradermics Doses First Patient in a First-in-Human Clinical Trial for VDPHL for the Treatment of Pattern Hair Loss (Androgenetic Alopecia)

Gaurav Munj2025-12-11T10:56:27+00:00 Newsroom 2023 News Top News Archives In the News Media Inquiries VDPHL is a once-daily non-hormonal oral therapeutic being developed as a treatment for pattern hair loss New Haven, CONN. (PRWeb) November 7, 2023   Veradermics Inc., a clinical-stage medical dermatology company with a pipeline of first-in-class product candidates...

Veradermics Doses First Patient in Phase 2 Clinical Trial for VDMN for the Treatment of Common Warts

Gaurav Munj2025-12-11T10:57:29+00:00 Newsroom 2023 News Top News Archives In the News Media Inquiries VDPHL is a once-daily non-hormonal oral therapeutic being developed as a treatment for pattern hair loss VDMN is an immunotherapy-containing dissolvable microarray being developed as an "injection-free" treatment for common warts   WEST HARTFORD, CONN. (PRWeb) March 24, 2023 Veradermics...

Veradermics Inc. Secures Licensing of First-in-Class Antiviral Targeting the Treatment of Molluscum Contagiosum and other Poxviruses

Gaurav Munj2025-12-11T10:57:06+00:00 Newsroom 2022 News Top News Archives In the News Media Inquiries WEST HARTFORD, CONN. (PRWEB) AUGUST 23, 2022   VeraDermics Incorporated, developer of drugs for dermatology, today announced that it has entered into a definitive license agreement with the University of Pennsylvania (Penn) for patent rights covering a newly...